Connection
Nicholas Foreman to Cisplatin
This is a "connection" page, showing publications Nicholas Foreman has written about Cisplatin.
|
|
Connection Strength |
|
|
|
|
|
0.550 |
|
|
|
-
Neuwelt AJ, Nguyen T, Wu YJ, Donson AM, Vibhakar R, Venkatamaran S, Amani V, Neuwelt EA, Rapkin LB, Foreman NK. Preclinical high-dose acetaminophen with N-acetylcysteine rescue enhances the efficacy of cisplatin chemotherapy in atypical teratoid rhabdoid tumors. Pediatr Blood Cancer. 2014 Jan; 61(1):120-7.
Score: 0.401
-
Matheson CJ, Venkataraman S, Amani V, Harris PS, Backos DS, Donson AM, Wempe MF, Foreman NK, Vibhakar R, Reigan P. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells. ACS Chem Biol. 2016 Apr 15; 11(4):921-30.
Score: 0.118
-
Prince EW, Balakrishnan I, Shah M, Mulcahy Levy JM, Griesinger AM, Alimova I, Harris PS, Birks DK, Donson AM, Davidson N, Remke M, Taylor MD, Handler MH, Foreman NK, Venkataraman S, Vibhakar R. Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. Oncotarget. 2016 Aug 16; 7(33):53881-53894.
Score: 0.031
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|